All questions are answered by: Richard Wenzel, PharmD Diamond Headache Clinic Inpatient Unit St. Josephýs Hospital, Chicago, IL Perhaps more than any group of medications, the triptans have contributed to the improved recognition and treatment of migraine and other types of headache. Introduced in the United States in 1993, these drugs have been an important catalyst for research, advanced healthcare professionalsý understanding of migraine, and offered an effective drug option to halt attacks, all of which ultimately benefitted thousands of migraine sufferers. There are now seven triptans available in the U.S. The triptans appear to act in migraine by binding to selected receptors for serotonin found in the blood vessels (5HT1B) and nerve endings (5HT1D). By binding to these receptors, triptans keep migraines from developing or cause them to end.

Zomig® is in a class of medications known as the "triptans." It is a specific medication for aborting migraine headaches. Zomig® is indicated for the acute treatment of migraine in adults. It is not intended for the prophylactic treatment of migraine and Zomig® has not been approved for the treatment of cluster headache. Zolmitriptan has been available in the United States since 1997. Currently it is available in 2.5 and 5 mg tablets as well as a nasal spray. It is also available as Zomig-ZMT 5 mg which is an orally disintegrating tablet that dissolves on the tongue without water. This formula is particularly helpful when nausea and vomiting accompany the migraine pain.